Desmopressin in Cardiac Surgery

Università Vita-Salute San Raffaele

Status and phase: Completed; Phase 4

Conditions: Hemorrhage; Postoperative Hemorrhage; Blood Loss, Surgical

Treatments: Drug: Placebo; Drug: Desmopressin (DDAVP)

Study type: Interventional

Funder types: Other

Identifiers

NCT00337766

DS/URC/ER/mm 151/DG

Details and patient eligibility

About

Patients undergoing cardiac surgery could develop excessive perioperative bleeding requiring transfusions of blood products.

Desmopressin (DDAVP), already used for patients with von Willebrand syndrome, could reduce bleeding and transfusion requirements in these patients when administered ev (0.3 mg/kg) in 20-30 minutes postoperatively.

Sex: All

Ages: 18 to 100 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• undergoing cardiac surgery
• excessive bleeding

Exclusion criteria

• age<18 y
• not signing written consent

Trial design

Primary purpose: Prevention

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

0 participants in 2 patient groups, including a placebo group

Desmopressin (DDAVP)

Active Comparator group

Treatment:

Drug: Desmopressin (DDAVP)

Placebo

Placebo Comparator group

Treatment:

Drug: Placebo